{
}
UBS analyst Eliana Merle has slashed the price target for Arvinas (ARVN) from $74.00 to $21.00, a decrease of approximately 71.62%, while maintaining a "Buy" rating, indicating continued long-term growth potential. The average price target from 17 analysts is now $20.21, suggesting a 234.53% upside from the current price of $6.04. GuruFocus estimates a fair value of $42.95 for the stock, implying a potential upside of 611.09%.
Kymera Therapeutics (KYMR) maintains a "Buy" rating from UBS, which has adjusted its price target from $72.00 to $70.00, reflecting a 2.78% decrease. Analysts forecast an average target price of $56.76, indicating an 81.97% upside from the current price of $31.20, while GuruFocus estimates a fair value of $21.64, suggesting a potential downside of 30.63%.
UBS has maintained a "Neutral" rating for BioNTech, setting a price target of $115 following the first quarter results, which revealed few surprises. Analyst Eliana Merle noted that the company is expected to see sales growth in the last quarter of the year, with potential long-term upside from its anti-cancer drug development.
UBS analyst Eliana Merle has raised the price target for Alnylam (ALNY) from $331 to $349, maintaining a Buy rating, citing strong early launch trends in transthyretin amyloid cardiomyopathy treatments. The average price target from 28 analysts is $321.04, indicating a potential upside of 23.72% from the current price of $259.48. Alnylam reported a 28% year-over-year growth in product revenues, reaching $469 million, with a notable 45% increase in its US TTR franchise.
CureVac (CVAC) has seen its price target reduced from $13 to $12 by UBS analyst Eliana Merle, who maintains a Buy recommendation, citing the company's mRNA platform and oncology pipeline as underappreciated. Analysts project an average target price of $6.32, indicating a potential upside of 76.41% from the current price of $3.59. The company reported a strong cash position of EUR481.7 million at the end of 2024 and achieved significant milestones, including a licensing agreement with GSK valued at up to EUR1.45 billion.
UBS analyst Eliana Merle has reiterated a Buy rating for Vertex Pharmaceuticals, setting a target price of $583.00, driven by strong momentum and expected growth in prescriptions for its drug Journavx, used for acute post-operative pain. The analysis indicates a potential increase in prescriptions, with positive feedback from healthcare professionals suggesting broader acceptance of the drug. Additionally, Vertex received European Commission approval for expanded use of its cystic fibrosis drug KAFTRIO®, further enhancing its market position.
UBS has maintained a Buy rating for Sarepta Therapeutics with a price target of $188, despite a recent patient death linked to its gene therapy Elevidys, which has caused the stock to drop over 26%. Analyst Eliana Merle views the market reaction as exaggerated and emphasizes the ongoing demand for Elevidys, the only approved treatment for Duchenne muscular dystrophy. While some analysts express caution regarding safety and sales forecasts, others remain optimistic about the drug's potential and future revenue growth.
Sarepta Therapeutics' shares saw volatility following a patient's death linked to its gene therapy, Elevidys, yet UBS analyst Eliana Merle maintained a Buy rating with a target of USD 188, viewing the market's reaction as an overreaction. Despite the incident, demand for Elevidys remains strong, and revenue growth is robust at 53% year-over-year. Analysts' responses vary, with some expressing caution while others uphold positive outlooks for the company's future performance.
UBS analyst Eliana Merle has reaffirmed a Buy rating on Sarepta Therapeutics (NASDAQ: SRPT) with a price target of $188.00. The positive outlook reflects confidence in the company's potential and market position.
UBS has reaffirmed its Buy rating on Madrigal Pharmaceuticals, setting a price target of $441, reflecting confidence in the company's potential in treating metabolic-associated steatohepatitis (MASH). Following strong fourth-quarter results, with revenues of $180 million and a gross margin of 96.54%, analysts remain optimistic about Madrigal's future, particularly with promising data from the Phase 3 MAESTRO-NAFLD-1 trial. The company holds a robust financial position, with cash and marketable securities totaling $931.3 million, and anticipates a potential European launch of its drug Rezdiffra in 2025, pending regulatory approval.
Eliana Merle
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
arvinas price target cut by ub s but buy rating remains intact
16:51 15.05.2025
ubs adjusts kymera therapeutics target price while maintaining buy rating
18:45 13.05.2025
UBS maintains neutral rating for BioNTech with price target of 115 dollars
09:22 07.05.2025
ubs raises alnylam price target amid strong early launch trends
16:15 02.05.2025
CureVac price target lowered by UBS amid strong financial and regulatory progress
16:02 30.04.2025
ubs maintains buy rating for vertex with target price of 583 dollars
17:44 22.04.2025
analysts divided on sarepta therapeutics after patient death linked to elevidys
United States Dollar
JPMorgan U.S. Research Enhanced Large Cap ETF
Leerink Partners LLC
Arrowhead Pharmaceuticals, Inc.
REGENXBIO Inc.
Cantor Fitzgerald Equity Opp A
H.C. Wainwright & Co. LLC
Sarepta Therapeutics, Inc.
USA
Eliana Merle
Show more
16:08 19.03.2025
analysts divided on sarepta therapeutics after patient death linked to elevidys
United States Dollar
JPMorgan U.S. Research Enhanced Large Cap ETF
Leerink Partners LLC
Arrowhead Pharmaceuticals, Inc.
REGENXBIO Inc.
Cantor Fitzgerald Equity Opp A
H.C. Wainwright & Co. LLC
Sarepta Therapeutics, Inc.
USA
Eliana Merle
Show more
16:08 19.03.2025
ubs maintains buy rating and price target for sarepta therapeutics
15:19 19.03.2025
ubs maintains buy rating on madrigal pharmaceuticals with target price of 441
17:17 27.02.2025
Trending
Subcategory
Countries:
Companies:
Currencies:
People: